Log In
Print
BCIQ
Print
Print this Print this
 

ITCA 650

  Manage Alerts
Collapse Summary General Information
Company Intarcia Therapeutics Inc.
DescriptionContinuous subcutaneous delivery of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, from the implantable Duros osmotic mini-pump
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentPhase III
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner

Quintiles Transnational Holdings Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today